SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Meng, Haitao ^a   Jin, Yingming ^a   Liu, Hui ^a   You, Liangshun ^a   Yang, Chunmei ^a   Yang, Xue ^a   Qian, Wenbin ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Akt; Cyclin dependent kinases; mTORC1; mTORC2; Perifosine; SNS 032

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PERIFOSINE; PROTEIN KINASE B; SOMATOMEDIN C;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CLINICAL ARTICLE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEUKEMIA CELL; MALE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MULTIPROTEIN COMPLEXES; OXAZOLES; PHOSPHORYLATION; PHOSPHORYLCHOLINE; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; THIAZOLES; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84873938940     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-18     Document Type: Article

References (38)

1. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF, Duncombe A, Gibson B, Wheatley K, J Clin Oncol 2010 28 586 595 10.1200/JCO.2009.22.9088 20038732
2. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German acute myeloid leukemia cooperative group. Büchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Kienast J, Staib P, J Clin Oncol 2009 27 61 69 19047294
3. Deregulation of signaling pathways in acute myeloid leukemia. Scholl C, Gilliland DG, Fröhling S, Semin Oncol 2008 35 336 345 10.1053/j.seminoncol. 2008.04.004 18692684
4. Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. Zhu X, Ma Y, Liu D, J Hematol Oncol 2010 23 3 17
5. Novel approaches to the treatment of acute myeloid leukemia. Roboz GJ, Hematology Am Soc Hematol Educ Program 2011 2011 43 50 10.1182/asheducation- 2011.1.43 22160011
6. Inhibitors of cyclin-dependent kinase modulators for cancer therapy. Senderowicz AM, Prog Drug Res 2005 63 183 206 10.1007/3-7643-7414-4-8 16265881 (Pubitemid 41406434)
7. Development of cell-cycle inhibitors for cancer therapy. Dickson MA, Schwartz GK, Curr Oncol 2009 16 36 43 19672423
8. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W, Blood 2009 113 4637 4645 10.1182/blood-2008-12-190256 19234140
9. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Chen R, Chubb S, Cheng T, Hawtin RE, Gandhi V, Plunkett W, Cancer Res 2010 70 6587 6597 10.1158/0008-5472.CAN-09-3578 20663900
10. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells. Wu Y, Chen C, Sun X, Shi X, Jin B, Ding K, Yeung SC, Pan J, Clin Cancer Res 2012 18 1966 1978 10.1158/1078-0432.CCR-11-1971 22447844
11. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, Badros AZ, Popplewell L, Coutre S, Fox JA, J Clin Oncol 2010 28 3015 3022 10.1200/JCO.2009.26.1347 20479412
12. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine. Walsby E, Lazenby M, Pepper C, Burnett AK, Leukemia 2011 25 411 419 10.1038/leu.2010.290 21212792
13. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, Green A, Mayeux P, Lacombe C, Bouscary D, Haematologica 2010 95 819 828 10.3324/haematol.2009.013797 19951971
14. mTOR complex 2 signaling and functions. Oh WJ, Jacinto E, Cell Cycle 2011 10 2305 2316 10.4161/cc.10.14.16586 21670596
15. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a New therapeutic strategy for acute myeloid leukemia. Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Clin Cancer Res 2010 16 5424 5435 10.1158/1078-0432.CCR-10-1102 20884625
16. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Gupta M, Hendrickson AE, Yun SS, Han JJ, Schneider PA, Koh BD, Stenson MJ, Wellik LE, Shing JC, Peterson KL, Blood 2012 119 476 487 10.1182/blood-2011-04-346601 22080480
17. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Blood 2012 120 2679 2689 10.1182/blood-2011- 11-393934 22826565
18. Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Wahner Hendrickson AE, Haluska P, Schneider PA, Loegering DA, Peterson KL, Attar R, Smith BD, Erlichman C, Gottardis M, Karp JE, Cancer Res 2009 69 7635 7643 10.1158/0008-5472.CAN-09-0511 19789352
19. Role of p70S6K1-mediated phosphorylation of eIF4B and PDCD4 in the regulation of protein synthesis. Dennis MD, Jefferson LS, Kimball SR, J Biol Chem 2012 287 42890 42899 10.1074/jbc.M112.404822 23105104
20. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Blood 2008 111 379 382 10.1182/blood-2007-03-080796 17878402
21. Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma. Pinton G, Manente AG, Angeli G, Mutti L, Moro L, PLoS One 2012 7 36856 10.1371/journal.pone.0036856 22590625
22. In vitro and In vivo inhibition of Neuroblastoma tumor cell growth by AKT inhibitor Perifosine. Li Z, Tan F, Liewehr DJ, Steinberg SM, Thiele CJ, J Natl Cancer Inst 2010 102 758 770 10.1093/jnci/djq125 20463309
23. Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl + hematological malignancies. Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Cancer Chemother Pharmacol 2012 69 1657 1667 10.1007/s00280-012-1839-5 22349810
24. mTOR-targeted therapy of cancer with rapamycin derivatives. Vignot S, Faivre S, Aguirre D, Raymond E, Ann Oncol 2005 16 525 537 10.1093/annonc/mdi113 15728109 (Pubitemid 40613318)
25. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Willems L, Uzunov M, Ifrah N, Dreyfus F, Lacombe C, Blood 2009 114 1618 1627 10.1182/blood-2008-10-184515 19458359
26. mTOR regulates cell survival after etoposide treatment in primary AML cells. Xu Q, Thompson JE, Carroll M, Blood 2005 106 4261 4268 10.1182/blood-2004-11-4468 16150937 (Pubitemid 41775935)
27. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Altman JK, Sassano A, Kaur S, Glaser H, Kroczynska B, Redig AJ, Russo S, Barr S, Platanias LC, Clin Cancer Res 2011 17 4378 4388 10.1158/1078-0432.CCR-10-2285 21415215
28. The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Polak R, Buitenhuis M, Blood 2012 119 911 923 10.1182/blood-2011-07-366203 22065598
29. The pharmacology of mTOR inhibition. Guertin DA, Sabatini DM, Sci Signal 2009 2 67 e24 Apr 21 10.1126/scisignal.267pe24 19383975
30. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Nat Med 2010 16 205 213 10.1038/nm.2091 20072130
31. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, Vignon C, Park S, Guichard S, Herault O, Leukemia 2012 26 1195 1202 10.1038/leu.2011.339 22143671
32. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick JS, Prie N, Verdier F, Vanhaesebroeck B, Muller O, Pesce F, Ifrah N, Blood 2005 106 1063 1066 10.1182/blood-2004-08-3225 15840695 (Pubitemid 41076455)
33. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Chapuis N, Tamburini J, Cornillet-Lefebvre P, Gillot L, Bardet V, Willems L, Park S, Green AS, Ifrah N, Dreyfus F, Haematologica 2010 95 415 423 10.3324/haematol.2009.010785 20007139
34. Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells. Ma Z, Zhu L, Luo X, Zhai S, Li P, Wang X, Cancer Biol Ther 2012 13 1009 1017 10.4161/cbt.20989 22825337
35. Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro. Tong Y, Liu YY, You LS, Qian WB, Acta Pharmacol Sin 2012 33 542 550 10.1038/aps.2011.192 22407228
36. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, Evangelisti C, Ottaviani E, Martinelli G, Testoni N, Leukemia 2008 22 147 160 10.1038/sj.leu.2404980 17928881
37. Akt inhibitors in clinical development for the treatment of cancer. Pal SK, Reckamp K, Yu H, Figlin RA, Expert Opin Investig Drugs 2010 19 1355 1366 10.1517/13543784.2010.520701 20846000
38. Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation. Jin J, Liu H, Yang C, Li G, Liu X, Qian Q, Qian W, Mol Cancer Ther 2009 8 1387 1397 10.1158/1535-7163.MCT-08-0962 19417152